KEYNOTE 185: This phase III trial is testing lenalidomide (a chemotherapy-like drug) and low-dose dexamethasone (a steroid) with and without pembrolizumab (an immunotherapy agent) for the treatment of newly diagnosed Multiple MyelomaA Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naive Multiple Myeloma

Inclusion

• Confirmed diagnosis of active multiple myeloma and measurable disease.
• Ineligible to receive treatment with auto-SCT due to age (≥65 years old) or any significant coexisting medical condition (cardiac, renal, pulmonary or hepatic dysfunction), likely to have a negative impact on tolerability of auto-SCT. Participants <65 years of age who refuse auto-SCT are not eligible for this study.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Female participants of childbearing potential must have 2 negative urine pregnancy tests (with a sensitivity of at least 25 Milli-international units/milliliter) within 10 to 14 days and within 24 hours prior to receiving study medication.
• Female participants of childbearing potential must agree to use adequate contraception 28 days prior to study start, continuing throughout the study, and for up to 28 days after the last dose of lenalidomide (or 120 days after the last dose of pembrolizumab).
• Male participants of childbearing potential must agree to use adequate contraception from the first dose of study medication, continuing throughout the study, and for up to 28 days after the last dose of lenalidomide (or 120 days after the last dose of pembrolizumab).